Elite Pharmaceuticals expands abuse deterrent technology
Edison Pharma announces EPI743 phase 2B3 Leigh Syndrome clinical trial with Dainippon Sumitomo
Bacterin International Holdings has secured $4 million in financing from investment firm OrbiMed
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Diagnos | 1 | 7 | 600 % |
| Alexion | 3 | 16 | 433 % |
| Ellipse Technologies | 1 | 5 | 400 % |
| Baxa | 1 | 5 | 400 % |
| Braintree Labs | 1 | 4 | 300 % |
| Straumann | 1 | 4 | 300 % |
| Galena Biopharma | 1 | 3 | 200 % |
| BSX | 2 | 6 | 200 % |
| Z-Medica | 13 | 36 | 177 % |
| Columbia Laboratories | 7 | 19 | 171 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| PharmAthene | 1 | 18 | 1700 % |
| Concert Pharmaceuticals | 1 | 15 | 1400 % |
| Cellular Dynamics | 4 | 44 | 1000 % |
| Capsule Technologies | 2 | 20 | 900 % |
| ChinaBio | 1 | 9 | 800 % |
| Keryx | 6 | 48 | 700 % |
| Neuralstem | 6 | 44 | 633 % |
| Supernus Pharmaceuticals | 1 | 7 | 600 % |
| Access Pharmaceuticals | 5 | 33 | 560 % |
| Apricus Biosciences | 5 | 33 | 560 % |